Tara C. Gangadhar

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Christina Twyman-Saint Victor, Andrew J. Rech, Amit Maity et al. · Nature · 2015 · 2.3K citations · Full text

Cancer Immunosurveillance, Medicine, Immunology +9

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014 · 1.7K citations

Oncology, Medicine, Ipilimumab-refractory Advanced Melanoma +10

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Alexander C. Huang, Michael A. Postow, Robert J. Orlowski et al. · Nature · 2017 · 1.6K citations · Full text

Burden Ratio, Cancer Immunosurveillance, Medicine +8

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer et al. · The Lancet Oncology · 2015 · 1.5K citations · Full text

Medicine, Melanoma, Immunology +10